Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
Merck & Company (6MK) Stock Price & Analysis
54 Followers
6MK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€91.00 - €125.60
Previous Close€115.4
Volume16.00
Average Volume (3M)531.00
Market Cap
€294.25B
Enterprise Value€320.56B
Total Cash (Recent Filing)$5.62B
Total Debt (Recent Filing)$34.22B
Price to Earnings (P/E)139.8
Beta<0.01
Next Earnings
Jul 30, 2024EPS Estimate
€1.99Next Dividend Ex-Date
Sep 16, 2024Dividend Yield2.44%
Share Statistics
EPS (TTM)0.82
Shares Outstanding2,532,806,307
10 Day Avg. Volume424
30 Day Avg. Volume531
Standard Deviation0.06
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)205.52
Price to Sales (P/S)5.11
Price to Cash Flow (P/CF)26.80
P/FCF Ratio33.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit7.29
Enterprise Value/Ebitda40.82
Forecast
1Y Price Target
€135.62Price Target Upside15.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTRx data for Keytruda and Gardasil suggest solid 2Q24 results.
Product LaunchStrong demand and building access could result in a strong Winrevair launch.
Vaccine ApprovalFDA approved MRK's Capvaxive (V116), a 21-valent adult-specific pneumococcal vaccine for the prevention of invasive disease and pneumonia in 18+ year olds.
Bears Say
Earnings RiskThe key risk to earnings is Keytruda’s patent expiry.
Market CompetitionThe company faces increasing competition in the pharmaceutical industry, which could pressure market share.
Regulatory ChallengesThe FDA issued a Complete Response Letter (CRL) for MRK/Daiichi Sankyo's patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with two or more systemic therapies.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
22.27% Mutual Funds
21.84% Other Institutional Investors
55.72% Public Companies and
Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €91.00 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Jul 30, 2024 which is in 5 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 25, 2024. The company reported €1.9 earnings per share for the quarter, beating the consensus estimate of €1.731 by €0.169.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.71 which represents an annual dividend yield of 2.44%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is €1.99.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,532,806,400 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.9 in its last earnings report, beating expectations of €1.731. Following the earnings report the stock price went up 1.516%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€135.62 (15.72% Upside)
€135.62 (15.72% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 90%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.83%
12-Months-Change
Fundamentals
Return on Equity
5.29%
Trailing 12-Months
Asset Growth
-1.81%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
6MK Company Deck
---
6MK Earnings Call
Q1 2024
0:00 / 0:00
---
6MK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€135.62
▲(15.72% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Bristol-Myers Squibb
―
Johnson & Johnson
―
Eli Lilly & Co
―
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+15.47%
reiterated a buy rating 2 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +15.47% per trade.
---